New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AA
Go back to New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AA| LOGICVISION (NASDAQ: LGVN) | Delayed: 0.59 -0.02 (3.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.61 | 52 Week High | $1.62 | |||
| Open | $0.62 | 52 Week Low | $0.35 | |||
| Day High | $0.63 | P/E | N/A | |||
| Day Low | $0.59 | EPS | $-0.17 | |||
| Volume | 113,753 | |||||
| (NASDAQ: LGVNR) | Delayed: 0.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.00 | 52 Week High | $ | |||
| Open | $2.45 | 52 Week Low | $ | |||
| Day High | $0.00 | P/E | N/A | |||
| Day Low | $0.00 | EPS | $ | |||
| Volume | 23,525,480 | |||||
